PHVSHealthcare · BiotechnologyThe 14 Wall Street analysts covering Pharvaris NV hold a median 12-month price target of $59 — +97.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Pharvaris NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (82): The shares have been drifting up relative to others.
Issuance (29): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PHVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +97.9% from it.
Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | Guggenheim | Maintains | Buy | $40 → $44 |
| 9 Sept 2026 | Citizens | Maintains | Market Outperform | $75 → $79 |
| 9 Sept 2026 | Leerink Partners | Maintains | Outperform | $50 → $65 |
| 9 Sept 2026 | Morgan Stanley | Maintains | Overweight | $46 → $62 |
| 9 Sept 2026 | RBC Capital | Maintains | Outperform | $52 → $62 |
| 9 Sept 2026 | Wedbush | Maintains | Outperform | $42 → $50 |
| 9 Sept 2026 | Wells Fargo | Maintains | Overweight | $55 → $65 |
| 8 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $60 |
| 8 Sept 2026 | Wedbush | Reiterates | Outperform | $42 |
| 13 Aug 2026 | Citizens | Maintains | Market Outperform | — |
| 13 Aug 2026 | Citizens | Maintains | Market Outperform | $74 → $75 |
| 13 Aug 2026 | Guggenheim | Maintains | Buy | $39 → $40 |
| 13 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 13 Aug 2026 | RBC Capital | Maintains | Outperform | $51 → $52 |
| 13 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 15 July 2026 | Wells Fargo | Initiates | Overweight | — |
| 15 July 2026 | Wells Fargo | Initiates | Overweight | $55 |
| 25 June 2026 | Morgan Stanley | Maintains | Overweight | $41 → $46 |
| 25 June 2026 | Morgan Stanley | Maintains | Overweight | — |
| 13 May 2026 | Citizens | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHVS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Pharvaris NV returned +43.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 15% of US stocks
Cheaper than 85% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 17% of US stocks
Higher than 10% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pharvaris NV has a market value of $2.1B and an enterprise value of $2.0B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$170.9M.
Free cash flow in the twelve months to 30 June 2026: −$155.3M.
Trailing P/E: −10.1×; forward P/E: −9.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Pharvaris NV employs 148 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Pharvaris NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Pharvaris announced that results from the phase 3 RAPIDe-3 study of oral deucrictibant immediate-release capsules for on-demand treatment of HAE attacks in adolescents and adults were published in The Lancet.
Why it matters — The publication reports on a phase 3 study of Pharvaris's investigational oral treatment for HAE attacks.
A real-world analysis on hereditary angioedema (HAE) disease experience and gaps in treatment satisfaction was published in Advances in Therapy, highlighting opportunities for further improvement in treatment use and adherence despite the availability of multiple long-term prophylaxis and on-demand treatment options.
Why it matters — The analysis identifies unmet needs and gaps in HAE treatment satisfaction that a PHVS watcher would find relevant to the competitive landscape of therapies in this space.
Pharvaris N.V. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation made available via Seeking Alpha.
Why it matters — The conference appearance gives PHVS watchers insight into the company's corporate and pipeline messaging as presented to investors at a major healthcare event.
Pharvaris shares have risen 10% over the past month, driven by strong phase III data showing its drug deucrictibant XR reduces hereditary angioedema attacks by 83%. The results support plans for regulatory submissions in 2027.
Why it matters — The robust efficacy data and upcoming regulatory milestones are key catalysts that PHVS watchers would track for the company's pipeline progress.
Seeking Alpha maintains a 'Strong Buy' rating on Pharvaris N.V. following pivotal phase 3 wins for both its on-demand and prophylactic hereditary angioedema therapies. The article highlights rapid symptom relief reported in the RAPIDe-3 trial.
Why it matters — PHVS watchers would care because positive phase 3 results for deucrictibant in both on-demand and prophylactic settings, along with the upcoming PDUFA, represent major clinical and regulatory milestones for the company.
The 14 Wall Street analysts covering Pharvaris NV have a median 12-month price target of $59, with estimates ranging from $41 to $78. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Pharvaris NV, 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pharvaris NV 39 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Oct 2026, Pharvaris NV ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +97.9% from the last close, and Ticker Nerd's factor model ranks Pharvaris NV 39 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Pharvaris NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $78 over the next 12 months.
Pharvaris NV returned +43.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet". Pharvaris announced that results from the phase 3 RAPIDe-3 study of oral deucrictibant immediate-release capsules for on-demand treatment of HAE attacks in adolescents and adults were published in The Lancet.
Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases. The company’s core work centers on bradykinin B2 receptor antagonists designed to address hereditary angioedema and related angioedema conditions through on-demand and preventive treatment options. Its current pipeline includes formulations intended for acute attack management as well as longer-acting prophylactic use, reflecting a portfolio built around differentiated oral approaches in a market still served by injectable and other traditional therapies. Pharvaris operates as a research-driven drug developer with activities spanning clinical development, regulatory engagement, and eventual commercialization of therapies for underserved patient populations. The company is headquartered in Zug, Switzerland.
CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A. · 148 employees · Switzerland · https://pharvaris.com
